Quetiapine for schizophrenia

Srisurapanont, Manit; Disayavanish, Chamlong; Taimkaew, K

doi:10.1002/14651858.cd000967

Cited by 46 publications

(58 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is comparable with the 26.5% withdrawal rate encountered with olanzapine in the same setting with a 6-month study duration [22] but substantially lower than that observed elsewhere [23]. A Cochrane Group review of 42 trials of quetiapine reported dropout rates of 36 Á64%, despite the fact that most of the trials were short term [23].…”

Section: Discussionsupporting

confidence: 59%

The “Seroquel” Outcomes Study (SOS): Efficacy and tolerability of quetiapine in a long-term, naturalistic study of patients with schizophrenia

Gibert¹,

Giner²,

Bobes³

et al. 2007

International Journal of Psychiatry in Clinical Practice

View full text Add to dashboard Cite

Objective. The "Seroquel" Outcomes Study (SOS) aimed to assess the efficacy and tolerability of quetiapine in patients with schizophrenia in the clinical practice setting. Methods. A 6-month, non-comparative, open-label study in adults with schizophrenia in a standard care setting in Spain. Outpatients received flexibly dosed quetiapine. Efficacy was evaluated using the Brief Psychiatry Rating Scale (BPRS) and the Clinical Global Impression (CGI) scale. BPRS response was defined as≥30% decrease from baseline. Tolerability was assessed using the Simpson-Angus Scale (SAS) and a modified Udvalg for Kliniske Undersogelser (UKU) side-effects scale. Results. A total of 2029 patients enrolled. Significant changes from baseline to Month 6 were recorded for BPRS total and subscale scores (P<0.001). Compared with doses of≥600 mg/day, doses of<400 mg/day were a strong predictor of a lower response rate (OR 0.62; 95% CI: 0.48, 0.82) and higher withdrawal rate (OR 3.3; 95% CI: 2.5, 4.4). Mean change in weight was minimal (+0.4 kg). Somnolence (26.7%), asthenia (12.5%), and constipation (9.8%) were the most common adverse events. Conclusion. Quetiapine was found to improve symptoms of schizophrenia, as indicated by a significant decrease in BPRS scores, and was well tolerated by patients in clinical practice.

show abstract

Section: Discussionsupporting

confidence: 59%

The “Seroquel” Outcomes Study (SOS): Efficacy and tolerability of quetiapine in a long-term, naturalistic study of patients with schizophrenia

Gibert¹,

Giner²,

Bobes³

et al. 2007

International Journal of Psychiatry in Clinical Practice

View full text Add to dashboard Cite

show abstract

“…Next, the reference lists of review articles and meta-analyses were examined to identify possible studies not found during the online search. For example, we checked the reference lists of the latest systematic reviews carried out by the Cochrane Collaboration which involved AAs available in the market [12][13][14][15][16][17][18][19] .…”

Section: Search Strategiesmentioning

confidence: 99%

Review of the efficacy of placebo in comparative clinical trials between typical and atypical antipsychotics

Oliveira

Nunes

Coutinho

et al. 2009

Rev. Bras. Psiquiatr.

View full text Add to dashboard Cite

show abstract

“…However, such drugs may induce some side effects such as acute Parkinsonism, tardive dyskinesia and neuroleptic malignant syndrome. [1][2][3][4][5][6][7] Sexual dysfunction is often not specifi cally evaluated in clinical studies. When it affects patients on drug therapy, it affects their self-esteem, causes trouble for their sexual partners, interferes with their quality of life and compromises treatment compliance.…”

Section: Introductionmentioning

confidence: 99%

A systematic review on clinical management of antipsychotic-induced sexual dysfunction in schizophrenia

2006

View full text Add to dashboard Cite

INTRODUCTION: Sexual dysfunction frequently occurs in patients with schizophrenia under antipsychotic therapy, and the presence of sexual side effects may affect compliance. The aim of this study was to review and describe clinical findings relating to the appropriate management of such dysfunctions. MATERIAL AND METHODS: The research was carried out through Medline (from 1966 to March 2005), PsycInfo (from 1974 to March 2005), and Cochrane Library (from 1965 to March 2005) and included any kind of study, from case reports to randomized trials. RESULTS: The most common sexual dysfunctions found in the literature were libido decrease, difficulties in achieving and maintaining erection, ejaculatory dysfunction, orgasmic dysfunction, and menstrual irregularities. Thirteen papers were found: eight of them were open-label studies, four were descriptions of cases, and only one was a randomized clinical trial. All of them were short-term and had small sample sizes. The agents used were: bromocriptine, cabergoline, cyproheptadine, amantadine, shakuyaku-kanzo-to, sildenafil and selegiline. DISCUSSION: There was no evidence that those agents had proper efficacy in treating the antipsychotic-induced sexual dysfunction. An algorithm for managing sexual dysfunction induced by antipsychotics is suggested as a support for clinical decisions. Since the outcome from schizophrenia treatment is strongly related to compliance with the antipsychotics, prevention of sexual dysfunction is better than its treatment, since there is a scarcity of data available regarding the efficacy of intervention to deal with these problems.

show abstract

Quetiapine for schizophrenia

Cited by 46 publications

References 44 publications

The “Seroquel” Outcomes Study (SOS): Efficacy and tolerability of quetiapine in a long-term, naturalistic study of patients with schizophrenia

The “Seroquel” Outcomes Study (SOS): Efficacy and tolerability of quetiapine in a long-term, naturalistic study of patients with schizophrenia

Review of the efficacy of placebo in comparative clinical trials between typical and atypical antipsychotics

A systematic review on clinical management of antipsychotic-induced sexual dysfunction in schizophrenia

Contact Info

Product

Resources

About